Key result
Inhibition of Nox4 with antisense oligonucleotides prevented the impairment of left ventricular ejection fraction and attenuated markers of cardiac injury in rats with early type 1 diabetes.
Why the study?
Does Nox4 inhibition prevent cardiomyocyte injury and contractility impairment in models of early type 1 diabetes?
Does Nox4 inhibition prevent cardiomyocyte injury and contractility impairment in models of early type 1 diabetes?
Absolute Event Rate: 73.44% vs 61.49%
p-value: p=<0.05
Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes, highlighting Nox4 as a potential therapeutic target for diabetic cardiomyopathy.
Supports Nox4 as target in rodent diabetic cardiomyopathy; hypothesis-generating for human translation.
Oxidative stress contributes to diabetic cardiomyopathy. This study explored the role of the NADPH oxidase Nox4 as a source of reactive oxygen species (ROS) involved in the development of diabetic cardiomyopathy. Phosphorothioated antisense (AS) or sense (S) oligonucleotides for Nox4 were administered for 2 wk to rats made diabetic by streptozotocin. NADPH oxidase activity, ROS generation, and the expression of Nox4, but Nox1 or Nox2, were increased in left ventricular tissue of the diabetic rats. Expression of molecular markers of hypertrophy and myofibrosis including fibronectin, collagen, α-smooth muscle actin, and β-myosin heavy chain were also increased. These parameters were attenuated by the administration of AS but not S Nox4. Moreover, the impairment of contractility observed in diabetic rats was prevented in AS- but not S-treated animals. Exposure of cultured cardiac myocytes to 25 mM glucose [high glucose (HG)] increased NADPH oxidase activity, the expression of Nox4, and molecular markers of cardiac injury. These effects of HG were prevented in cells infected with adenoviral vector containing a dominant negative form of Nox4. This study provides strong evidence that Nox4 is an important source of ROS in the left ventricle and that Nox4-derived ROS contribute to cardiomyopathy at early stages of type 1 diabetes.
No takes yet. Share an insight, caveat, or question.
Maalouf et al. (2011) studied Diabetic cardiomyopathy in early type 1 diabetes (n=16). Phosphorothioated antisense oligonucleotides for Nox4 vs. Phosphorothioated sense oligonucleotides for Nox4 or vehicle was evaluated on Left ventricular ejection fraction (p=<0.05). Inhibition of Nox4 with antisense oligonucleotides prevented the impairment of left ventricular ejection fraction and attenuated markers of cardiac injury in rats with early type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: